Fate Therapeutics (FATE) Liabilities and Shareholders Equity (2012 - 2026)

Fate Therapeutics (FATE) has 15 years of Liabilities and Shareholders Equity data on file, last reported at $284.9 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 28.53% year-over-year to $284.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (down 29.2% YoY) and the FY2025 annual result came in at $318.9 million, down 27.63% from the prior year.
• Liabilities and Shareholders Equity eased to $284.9 million in Q1 2026, from $318.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $858.4 million in Q1 2022 to a low of $284.9 million in Q1 2026.
• A 5-year average of $537.5 million and a median of $528.8 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity dropped 8.98% — and 2025, when it tumbled 30.57%.
• Tracing FATE's Liabilities and Shareholders Equity over 5 years: stood at $705.6 million in 2022, then declined by 28.25% to $506.2 million in 2023, then declined by 12.94% to $440.7 million in 2024, then decreased by 27.63% to $318.9 million in 2025, then declined by 10.67% to $284.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $284.9 million (Q1 2026), $318.9 million (Q4 2025), and $343.7 million (Q3 2025), per Business Quant data.